REFERENCES
1. Wolffsohn JS, Benítez-Del-Castillo JM, Loya-Garcia D, et al.; + TFOS collaborator group. TFOS DEWS III: diagnostic methodology. Am J Ophthalmol. 2025;279:387-450.
2. Ljubica J, Dukovski BJ, Krtalić I, et al. Overcoming barriers in formulating practically insoluble loteprednol etabonate in ophthalmic nanoemulsion. Eur J Pharm Sci. 2025;209:107077.
3. Kwon J, Moghtader A, Kang C, et al. Overview of dry eye disease for primary care physicians. Medicina. 2025;61:460.
4. Mohamed HB, Abd El-Hamid BN, Fathalla D, Fouad EA. Current trends in pharmaceutical treatment of dry eye disease: a review. Eur J Pharm Sci. 2022;175:106206.
5. Phinney DG, Pittenger MF. Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells. 2017;35:851-8.
6. Song N, Scholtemeijer M, Shah K. Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential. Trends Pharmacol Sci. 2020;41:653-64.
7. Buchert JM, Lotz B, Diederichs S, Richter W. Adipose-derived stromal cells: isolation, expansion, and differentiation. Methods Mol Biol. 2023;2598:75-85.
8. Li H, Ghazanfari R, Zacharaki D, Lim HC, Scheding S. Isolation and characterization of primary bone marrow mesenchymal stromal cells. Ann N Y Acad Sci. 2016;1370:109-18.
9. Stefańska K, Volponi AA, Kulus M, et al. Dental pulp stem cells - a basic research and future application in regenerative medicine. Biomed Pharmacother. 2024;178:116990.
10. Margiana R, Markov A, Zekiy AO, et al. Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review. Stem Cell Res Ther. 2022;13:366.
11. Beeravolu N, McKee C, Alamri A, et al. Isolation and characterization of mesenchymal stromal cells from human umbilical cord and fetal placenta. J Vis Exp. 2017;122:55224.
12. Abbaszadeh H, Ghorbani F, Derakhshani M, et al. Regenerative potential of Wharton’s jelly-derived mesenchymal stem cells: a new horizon of stem cell therapy. J Cell Physiol. 2020;235:9230-40.
13. Zare E, Hosseini ES, Azad FS, et al. Replicative senescence in amniotic fluid-derived mesenchymal stem cells and its impact on their immunomodulatory properties. Histochem Cell Biol. 2025;163:34.
14. Reis M, Mavin E, Nicholson L, Green K, Dickinson AM, Wang XN. Mesenchymal stromal cell-derived extracellular vesicles attenuate dendritic cell maturation and function. Front Immunol. 2018;9:2538.
15. Sikora B, Skubis-Sikora A, Prusek A, Gola J. Paracrine activity of adipose derived stem cells on limbal epithelial stem cells. Sci Rep. 2021;11:19956.
16. Alvites R, Branquinho M, Sousa AC, Lopes B, Sousa P, Maurício AC. Mesenchymal stem/stromal cells and their paracrine activity-immunomodulation mechanisms and how to influence the therapeutic potential. Pharmaceutics. 2022;14:381.
17. Zhou Y, Yamamoto Y, Xiao Z, Ochiya T. The immunomodulatory functions of mesenchymal stromal/stem cells mediated via paracrine activity. J Clin Med. 2019;8:1025.
18. Møller-Hansen M. Mesenchymal stem cell therapy in aqueous deficient dry eye disease. Acta Ophthalmol. 2023;101:3-27.
19. Harrell CR, Djonov V, Volarevic A, Arsenijevic A, Volarevic V. Molecular mechanisms responsible for mesenchymal stem cell-dependent attenuation of tear hyperosmolarity and immune cell-driven inflammation in the eyes of patients with dry eye disease. Diseases. 2024;12:269.
20. Yaghoubi Y, Movassaghpour A, Zamani M, Talebi M, Mehdizadeh A, Yousefi M. Human umbilical cord mesenchymal stem cells derived-exosomes in diseases treatment. Life Sci. 2019;233:116733.
21. Zhou T, He C, Lai P, et al. miR-204-containing exosomes ameliorate GVHD-associated dry eye disease. Sci Adv. 2022;8:eabj9617.
22. Farrand KF, Fridman M, Stillman IÖ, Schaumberg DA. Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. Am J Ophthalmol. 2017;182:90-8.
23. Cai Y, Wei J, Zhou J, Zou W. Prevalence and incidence of dry eye disease in Asia: a systematic review and meta-analysis. Ophthalmic Res. 2022;65:647-58.
24. Stapleton F, Argüeso P, Asbell P, et al. TFOS DEWS III: digest. Am J Ophthalmol. 2025;279:451-553.
25. Sheppard J, Shen Lee B, Periman LM. Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists. Ann Med. 2023;55:241-52.
26. Jones L, Craig JP, Markoulli M, et al.; TFOS Collaborator Group. TFOS DEWS III: management and therapy. Am J Ophthalmol. 2025;279:289-386.
27. Rana HS, Akella SS, Clabeaux CE, Skurski ZP, Aakalu VK. Ocular surface disease in thyroid eye disease: a narrative review. Ocul Surf. 2022;24:67-73.
28. Huang R, Su C, Fang L, Lu J, Chen J, Ding Y. Dry eye syndrome: comprehensive etiologies and recent clinical trials. Int Ophthalmol. 2022;42:3253-72.
29. Donthineni PR, Das AV, Basu S. Dry eye disease in children and adolescents in India. Ocul Surf. 2020;18:777-82.
30. Leonardi A, Di Zazzo A, Cutrupi F, Iaccarino L. Dry eye and systemic diseases. Saudi J Ophthalmol. 2025;39:5-13.
31. Truong S, Cole N, Stapleton F, Golebiowski B. Sex hormones and the dry eye. Clin Exp Optom. 2014;97:324-36.
32. Stapleton F, Velez FG, Lau C, Wolffsohn JS. Dry eye disease in the young: a narrative review. Ocul Surf. 2024;31:11-20.
33. Narang P, Donthineni PR, D’Souza S, Basu S. Evaporative dry eye disease due to meibomian gland dysfunction: preferred practice pattern guidelines for diagnosis and treatment. Indian J Ophthalmol. 2023;71:1348-56.
34. Rolando M, Merayo-Lloves J. Management strategies for evaporative dry eye disease and future perspective. Curr Eye Res. 2022;47:813-23.
35. Ma J, Zhu H, Guo W, et al. Association of different digital media experiences with paediatric dry eye in China: a population-based study. BMJ Open. 2022;12:e062850.
36. Wang MTM, Craig JP, Vidal-Rohr M, et al. Impact of digital screen use and lifestyle factors on dry eye disease in the paediatric population. Ocul Surf. 2022;24:64-6.
37. Tovar AA, Frankel ST, Galor A, Sabater AL. Living with dry eye disease and its effects on quality of life: patient, optometrist, and ophthalmologist perspectives. Ophthalmol Ther. 2023;12:2219-26.
38. Santos G, Delgado E, Silva B, Braz BS, Gonçalves L. Topical ocular drug delivery: the impact of permeation enhancers. Pharmaceutics. 2025;17:447.
39. Willcox MDP, Argüeso P, Georgiev GA, et al. TFOS DEWS II tear film report. Ocul Surf. 2017;15:366-403.
40. Winiarczyk M, Biela K, Michalak K, Winiarczyk D, Mackiewicz J. Changes in tear proteomic profile in ocular diseases. Int J Environ Res Public Health. 2022;19:13341.
41. Liu H, Begley C, Chen M, et al. A link between tear instability and hyperosmolarity in dry eye. Invest Ophthalmol Vis Sci. 2009;50:3671-9.
42. Guindolet D, Woodward AM, Gabison EE, Argüeso P. Alleviation of endoplasmic reticulum stress enhances human corneal epithelial cell viability under hyperosmotic conditions. Int J Mol Sci. 2022;23:4528.
43. Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15:802-12.
44. Bron AJ, Willshire C. Tear osmolarity in the diagnosis of systemic dehydration and dry eye disease. Diagnostics. 2021;11:387.
45. Harrell CR, Volarevic V. Ion channels as potential drug targets in dry eye disease and their clinical relevance: a review. Cells. 2024;13:2017.
46. Guzmán M, Miglio M, Keitelman I, et al. Transient tear hyperosmolarity disrupts the neuroimmune homeostasis of the ocular surface and facilitates dry eye onset. Immunology. 2020;161:148-61.
47. Zhuang D, Misra SL, Mugisho OO, Rupenthal ID, Craig JP. NLRP3 inflammasome as a potential therapeutic target in dry eye disease. Int J Mol Sci. 2023;24:10866.
49. Pan Z, Wang Z, Yang H, Zhang F, Reinach PS. TRPV1 activation is required for hypertonicity-stimulated inflammatory cytokine release in human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2011;52:485-93.
50. Luo L, Li DQ, Pflugfelder SC. Hyperosmolarity-induced apoptosis in human corneal epithelial cells is mediated by cytochrome c and MAPK pathways. Cornea. 2007;26:452-60.
51. Pflugfelder SC, Stern ME. The cornea in keratoconjunctivitis sicca. Exp Eye Res. 2020;201:108295.
52. Wang HH, Chen WY, Huang YH, et al. Interleukin-20 is involved in dry eye disease and is a potential therapeutic target. J Biomed Sci. 2022;29:36.
53. Kumar R, DuMond JF, Khan SH, et al. NFAT5, which protects against hypertonicity, is activated by that stress via structuring of its intrinsically disordered domain. Proc Natl Acad Sci U S A. 2020;117:20292-7.
54. Dai Y, Zhang J, Xiang J, Li Y, Wu D, Xu J. Calcitriol inhibits ROS-NLRP3-IL-1β signaling axis via activation of Nrf2-antioxidant signaling in hyperosmotic stress stimulated human corneal epithelial cells. Redox Biol. 2019;21:101093.
55. Zhang J, Dai Y, Yang Y, Xu J. Calcitriol alleviates hyperosmotic stress-induced corneal epithelial cell damage via inhibiting the NLRP3-ASC-Caspase-1-GSDMD pyroptosis pathway in dry eye disease. J Inflamm Res. 2021;14:2955-62.
56. Chen H, Gan X, Li Y, et al. NLRP12- and NLRC4-mediated corneal epithelial pyroptosis is driven by GSDMD cleavage accompanied by IL-33 processing in dry eye. Ocul Surf. 2020;18:783-94.
57. Yang X, Zuo X, Zeng H, et al. IFN-γ facilitates corneal epithelial cell pyroptosis through the JAK2/STAT1 pathway in dry eye. Invest Ophthalmol Vis Sci. 2023;64:34.
58. Han Y, Zhang Y, Yuan K, Wu Y, Jin X, Huang X. Hyperosmolarity promotes macrophage pyroptosis by driving the glycolytic reprogramming of corneal epithelial cells in dry eye disease. Front Med. 2023;17:781-95.
59. Deng K, Li W, Liang J, et al. Peptide DFCPPGFNTK mitigates dry eye pathophysiology by suppressing oxidative stress, apoptosis, inflammation, and autophagy: evidence from in vitro and in vivo models. Curr Issues Mol Biol. 2025;47:441.
60. Bu J, Liu Y, Zhang R, et al. Potential new target for dry eye disease-oxidative stress. Antioxidants. 2024;13:422.
61. Jiang E, Jin H, Liu J, et al. Comparison of the therapeutic effects of rebamipide and diquafosol on apoptotic damage of the ocular surface in dry eyes. Antioxidants. 2025;14:780.
62. Hu R, Shi J, Xie CM, Yao XL. Dry eye disease: oxidative stress on ocular surface and cutting-edge antioxidants. Glob Chall. 2025;9:e00068.
63. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15:276-83.
64. Ashok N, Khamar P, D’Souza S, et al. Ion channels in dry eye disease. Indian J Ophthalmol. 2023;71:1215-26.
65. Kang MJ, Kim HS, Kim MS, Kim EC. The correlation between matrix metalloproteinase-9 point-of-care immunoassay, tear film osmolarity, and ocular surface parameters. J Ophthalmol. 2022;2022:6132016.
66. Choi M, Park YM, Ko BY. Comparative evaluation of matrix metalloproteinase-9 immunoassay and tear osmolarity measurement for diagnosing severity of dry eye disease. Korean J Ophthalmol. 2023;37:409-16.
67. Jamerson EC, Elhusseiny AM, ElSheikh RH, Eleiwa TK, El Sayed YM. Role of matrix metalloproteinase 9 in ocular surface disorders. Eye Contact Lens. 2020;46:S57-63.
68. Harrell CR, Feulner L, Djonov V, Pavlovic D, Volarevic V. The molecular mechanisms responsible for tear hyperosmolarity-induced pathological changes in the eyes of dry eye disease patients. Cells. 2023;12:2755.
69. Li DQ, Luo L, Chen Z, Kim HS, Song XJ, Pflugfelder SC. JNK and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells. Exp Eye Res. 2006;82:588-96.
71. Luo L, Li DQ, Doshi A, Farley W, Corrales RM, Pflugfelder SC. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci. 2004;45:4293-301.
72. Perez VL, Stern ME, Pflugfelder SC. Inflammatory basis for dry eye disease flares. Exp Eye Res. 2020;201:108294.
73. Zhao D, Ji H, Zhao H, Xu Y, He A, He Y. BMSC-derived exosomes regulate the Treg/Th17 balance through the miR-21-5p/TLR4/MyD88/NF-κB pathway to alleviate dry eye symptoms in mice. In Vitro Cell Dev Biol Anim. 2024;60:644-56.
74. Reins RY, Lema C, Courson J, Kunnen CME, Redfern RL. MyD88 deficiency protects against dry eye-induced damage. Invest Ophthalmol Vis Sci. 2018;59:2967-76.
75. Zheng Q, Ren Y, Reinach PS, et al. Reactive oxygen species activated NLRP3 inflammasomes initiate inflammation in hyperosmolarity stressed human corneal epithelial cells and environment-induced dry eye patients. Exp Eye Res. 2015;134:133-40.
76. Ren Y, Feng J, Lin Y, et al. MiR-223 inhibits hyperosmolarity-induced inflammation through downregulating NLRP3 activation in human corneal epithelial cells and dry eye patients. Exp Eye Res. 2022;220:109096.
77. Chi W, Hua X, Chen X, et al. Mitochondrial DNA oxidation induces imbalanced activity of NLRP3/NLRP6 inflammasomes by activation of caspase-8 and BRCC36 in dry eye. J Autoimmun. 2017;80:65-76.
78. Yin X, Chen S, Eisenbarth SC. Dendritic cell regulation of T helper cells. Annu Rev Immunol. 2021;39:759-90.
79. Reyes JL, Vannan DT, Eksteen B, et al. Innate and adaptive cell populations driving inflammation in dry eye disease. Mediators Inflamm. 2018;2018:2532314.
80. Pflugfelder SC, Corrales RM, de Paiva CS. T helper cytokines in dry eye disease. Exp Eye Res. 2013;117:118-25.
81. Barabino S, Chen Y, Chauhan S, Dana R. Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease. Prog Retin Eye Res. 2012;31:271-85.
82. Zimmer N, Trzeciak ER, Graefen B, Satoh K, Tuettenberg A. GARP as a therapeutic target for the modulation of regulatory T cells in cancer and autoimmunity. Front Immunol. 2022;13:928450.
83. Jung YH, Ryu JS, Yoon CH, Kim MK. Age-dependent distinct distributions of dendritic cells in autoimmune dry eye murine model. Cells. 2021;10:1857.
84. Liu Z, Xie H, Li L, et al. Single-cell landscape reveals the epithelial cell-centric pro-inflammatory immune microenvironment in dry eye development. Mucosal Immunol. 2024;17:491-507.
85. Schaumburg CS, Siemasko KF, De Paiva CS, et al. Ocular surface APCs are necessary for autoreactive T cell-mediated experimental autoimmune lacrimal keratoconjunctivitis. J Immunol. 2011;187:3653-62.
86. De Paiva CS, Chotikavanich S, Pangelinan SB, et al. IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol. 2009;2:243-53.
87. Stern ME, Schaumburg CS, Dana R, Calonge M, Niederkorn JY, Pflugfelder SC. Autoimmunity at the ocular surface: pathogenesis and regulation. Mucosal Immunol. 2010;3:425-42.
88. Pham TL, Bazan HEP. Docosanoid signaling modulates corneal nerve regeneration: effect on tear secretion, wound healing, and neuropathic pain. J Lipid Res. 2021;62:100033.
89. Fakih D, Zhao Z, Nicolle P, et al. Chronic dry eye induced corneal hypersensitivity, neuroinflammatory responses, and synaptic plasticity in the mouse trigeminal brainstem. J Neuroinflammation. 2019;16:268.
90. Sebbag L, Thomasy SM, Leland A, Mukai M, Kim S, Maggs DJ. Altered corneal innervation and ocular surface homeostasis in FHV-1-exposed cats: a preliminary study suggesting metaherpetic disease. Front Vet Sci. 2020;7:580414.
91. Belmonte C, Nichols JJ, Cox SM, et al. TFOS DEWS II pain and sensation report. Ocul Surf. 2017;15:404-37.
92. Tepelus TC, Chiu GB, Huang J, et al. Correlation between corneal innervation and inflammation evaluated with confocal microscopy and symptomatology in patients with dry eye syndromes: a preliminary study. Graefes Arch Clin Exp Ophthalmol. 2017;255:1771-8.
93. Xu J, Chen P, Yu C, Liu Y, Hu S, Di G. In vivo confocal microscopic evaluation of corneal dendritic cell density and subbasal nerve parameters in dry eye patients: a systematic review and meta-analysis. Front Med. 2021;8:578233.
94. Cox SM, Kheirkhah A, Aggarwal S, et al. Alterations in corneal nerves in different subtypes of dry eye disease: an in vivo confocal microscopy study. Ocul Surf. 2021;22:135-42.
95. Jamali A, Seyed-Razavi Y, Chao C, et al. Intravital multiphoton microscopy of the ocular surface: alterations in conventional dendritic cell morphology and kinetics in dry eye disease. Front Immunol. 2020;11:742.
96. Møller-Hansen M, Larsen AC, Toft PB, et al. Safety and feasibility of mesenchymal stem cell therapy in patients with aqueous deficient dry eye disease. Ocul Surf. 2021;19:43-52.
97. Betz J, Galor A. Navigating the dry eye therapeutic puzzle: a mechanism-based overview of current treatments. Pharmaceuticals. 2025;18:994.
98. Tong L, Liu Z, Şahin A, et al. Topical pharmacologic treatments for dry eye disease: a systematic review. Ocul Surf. 2025;38:302-17.
99. Harrell CR, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Mesenchymal stem cell-derived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases. Cells. 2019;8:1605.
100. Shen Z, Huang W, Liu J, Tian J, Wang S, Rui K. Effects of mesenchymal stem cell-derived exosomes on autoimmune diseases. Front Immunol. 2021;12:749192.
101. Li N, Zhao L, Wei Y, Ea VL, Nian H, Wei R. Recent advances of exosomes in immune-mediated eye diseases. Stem Cell Res Ther. 2019;10:278.
102. Bhujel B, Oh SH, Kim CM, et al. Mesenchymal stem cells and exosomes: a novel therapeutic approach for corneal diseases. Int J Mol Sci. 2023;24:10917.
103. Pitt JM, Kroemer G, Zitvogel L. Extracellular vesicles: masters of intercellular communication and potential clinical interventions. J Clin Invest. 2016;126:1139-43.
104. Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255-89.
105. Li SJ, Cheng RJ, Wei SX, Xia ZJ, Pu YY, Liu Y. Advances in mesenchymal stem cell-derived extracellular vesicles therapy for Sjogren’s syndrome-related dry eye disease. Exp Eye Res. 2023;237:109716.
106. Kim H, Lee MJ, Bae EH, et al. Comprehensive molecular profiles of functionally effective MSC-derived extracellular vesicles in immunomodulation. Mol Ther. 2020;28:1628-44.
107. Harrell CR, Fellabaum C, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Molecular mechanisms responsible for therapeutic potential of mesenchymal stem cell-derived secretome. Cells. 2019;8:467.
108. Sun SJ, Wei R, Li F, Liao SY, Tse HF. Mesenchymal stromal cell-derived exosomes in cardiac regeneration and repair. Stem Cell Reports. 2021;16:1662-73.
109. Morandi MI, Busko P, Ozer-Partuk E, et al. Extracellular vesicle fusion visualized by cryo-electron microscopy. PNAS Nexus. 2022;1:pgac156.
110. Mathew B, Ravindran S, Liu X, et al. Mesenchymal stem cell-derived extracellular vesicles and retinal ischemia-reperfusion. Biomaterials. 2019;197:146-60.
111. van Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19:213-28.
112. Fu X, Liu G, Halim A, Ju Y, Luo Q, Song AG. Mesenchymal stem cell migration and tissue repair. Cells. 2019;8:784.
114. Louie HH, Mugisho OO, Chamley LW, Rupenthal ID. Extracellular vesicles as biomarkers and therapeutics for inflammatory eye diseases. Mol Pharm. 2023;20:23-40.
115. Kolenc A, Maličev E. Current methods for analysing mesenchymal stem cell-derived extracellular vesicles. Int J Mol Sci. 2024;25:3439.
116. Holcar M, Kandušer M, Lenassi M. Blood nanoparticles - influence on extracellular vesicle isolation and characterization. Front Pharmacol. 2021;12:773844.
117. Murphy DE, de Jong OG, Brouwer M, et al. Extracellular vesicle-based therapeutics: natural versus engineered targeting and trafficking. Exp Mol Med. 2019;51:1-12.
118. Toh WS, Lai RC, Zhang B, Lim SK. MSC exosome works through a protein-based mechanism of action. Biochem Soc Trans. 2018;46:843-53.
119. Bhujel B, Shin HE, Choi DJ, Han I. Mesenchymal stem cell-derived exosomes and intervertebral disc regeneration: review. Int J Mol Sci. 2022;23:7306.
120. Hefley BS, Deighan C, Vasini B, et al. Revealing the presence of tear extracellular vesicles in Keratoconus. Exp Eye Res. 2022;224:109242.
121. Amin S, Jalilian E, Katz E, et al. The limbal niche and regenerative strategies. Vision. 2021;5:43.
122. Jalilian E, Massoumi H, Bigit B, et al. Bone marrow mesenchymal stromal cells in a 3D system produce higher concentration of extracellular vesicles (EVs) with increased complexity and enhanced neuronal growth properties. Stem Cell Res Ther. 2022;13:425.
123. Rassi DM, De Paiva CS, Dias LC, et al. Review: microRNAS in ocular surface and dry eye diseases. Ocul Surf. 2017;15:660-9.
124. Munir J, Yoon JK, Ryu S. Therapeutic miRNA-enriched extracellular vesicles: current approaches and future prospects. Cells. 2020;9:2271.
125. Qian X, An N, Ren Y, Yang C, Zhang X, Li L. Immunosuppressive effects of mesenchymal stem cells-derived exosomes. Stem Cell Rev Rep. 2021;17:411-27.
126. Xu HK, Chen LJ, Zhou SN, Li YF, Xiang C. Multifunctional role of microRNAs in mesenchymal stem cell-derived exosomes in treatment of diseases. World J Stem Cells. 2020;12:1276-94.
127. Wang L, Wang X, Chen Q, et al. MicroRNAs of extracellular vesicles derived from mesenchymal stromal cells alleviate inflammation in dry eye disease by targeting the IRAK1/TAB2/NF-κB pathway. Ocul Surf. 2023;28:131-40.
128. Habibi A, Khosravi A, Soleimani M, Nejabat M, Dara M, Azarpira N. Efficacy of topical mesenchymal stem cell exosome in Sjögren’s syndrome-related dry eye: a randomized clinical trial. BMC Ophthalmol. 2025;25:299.
129. Chan SM, Tsai C, Lee TP, Huang ZR, Huang WH, Lin CT. Therapeutic potential of umbilical cord MSC-derived exosomes in a severe dry eye rat model: enhancing corneal protection and modulating inflammation. Biomedicines. 2025;13:1174.
130. Wang G, Zhu Y, Liu Y, Yang M, Zeng L. Mesenchymal stem cells-derived exosomal miR-223-3p alleviates ocular surface damage and inflammation by downregulating Fbxw7 in dry eye models. Invest Ophthalmol Vis Sci. 2024;65:1.
131. Yu C, Chen P, Xu J, et al. hADSCs derived extracellular vesicles inhibit NLRP3inflammasome activation and dry eye. Sci Rep. 2020;10:14521.
132. Wang G, Li H, Long H, Gong X, Hu S, Gong C. Exosomes derived from mouse adipose-derived mesenchymal stem cells alleviate benzalkonium chloride-induced mouse dry eye model via inhibiting NLRP3 inflammasome. Ophthalmic Res. 2022;65:40-51.
133. Chopra P, Fatima A, Mohapatra S, et al. Extracellular vesicles in dry eye disease and Sjögren’s syndrome: a systematic review on their diagnostic and therapeutic role. Surv Ophthalmol. 2025;70:499-515.
134. Guo R, Liang Q, He Y, et al. Mesenchymal stromal cells-derived extracellular vesicles regulate dendritic cell functions in dry eye disease. Cells. 2022;12:33.
135. Li N, Gao Z, Zhao L, et al. MSC-derived small extracellular vesicles attenuate autoimmune dacryoadenitis by promoting M2 macrophage polarization and inducing Tregs via miR-100-5p. Front Immunol. 2022;13:888949.
136. Yan L, Wang J, Cai X, et al. Macrophage plasticity: signaling pathways, tissue repair, and regeneration. MedComm. 2024;5:e658.
137. Ren Y, Wang Y, An N, et al. Periodontal ligament stem cell-derived exosomes regulate Muc5ac expression in rat conjunctival goblet cells via regulating macrophages toward an anti-inflammatory phenotype. Ocul Immunol Inflamm. 2024;32:1990-9.
138. Bjordal O, Norheim KB, Rødahl E, Jonsson R, Omdal R. Primary Sjögren’s syndrome and the eye. Surv Ophthalmol. 2020;65:119-32.
139. Li B, Xing Y, Gan Y, He J, Hua H. Labial gland-derived mesenchymal stem cells and their exosomes ameliorate murine Sjögren’s syndrome by modulating the balance of Treg and Th17 cells. Stem Cell Res Ther. 2021;12:478.
140. Ma D, Wu Z, Zhao X, et al. Immunomodulatory effects of umbilical mesenchymal stem cell-derived exosomes on CD4+ T cells in patients with primary Sjögren’s syndrome. Inflammopharmacology. 2023;31:1823-38.
141. Xing Y, Li B, He J, Hua H. Labial gland mesenchymal stem cell derived exosomes-mediated miRNA-125b attenuates experimental Sjogren’s syndrome by targeting PRDM1 and suppressing plasma cells. Front Immunol. 2022;13:871096.
142. Shen T, Zheng QQ, Shen J, et al. Effects of adipose-derived mesenchymal stem cell exosomes on corneal stromal fibroblast viability and extracellular matrix synthesis. Chin Med J. 2018;131:704-12.
143. Dogru M, Matsumoto Y, Yamamoto Y, et al. Lactoferrin in Sjögren’s syndrome. Ophthalmology. 2007;114:2366-7.
144. Foulsham W, Dohlman TH, Mittal SK, et al. Thrombospondin-1 in ocular surface health and disease. Ocul Surf. 2019;17:374-83.
145. Liu X, Li X, Wu G, et al. Umbilical cord mesenchymal stem cell-derived small extracellular vesicles deliver miR-21 to promote corneal epithelial wound healing through PTEN/PI3K/Akt pathway. Stem Cells Int. 2022;2022:1252557.
146. Tati V, Mitra S, Basu S, Shukla S. Bone marrow mesenchymal stem cell-derived extracellular vesicles promote corneal epithelial repair and suppress apoptosis via modulation of Caspase-3 in vitro. FEBS Open Bio. 2024;14:968-82.
147. Tati V, Muthukumar VS, Shukla S. Mesenchymal vs. epithelial extracellular vesicles in corneal epithelial repair, apoptosis, and immunomodulation: an in vitro study. Exp Eye Res. 2024;247:110027.
148. Ryu Y, Hwang JS, Bo Noh K, Park SH, Seo JH, Shin YJ. Adipose mesenchymal stem cell-derived exosomes promote the regeneration of corneal endothelium through ameliorating senescence. Invest Ophthalmol Vis Sci. 2023;64:29.
149. Liu Q, Li D, Pan X, Liang Y. Targeted therapy using engineered extracellular vesicles: principles and strategies for membrane modification. J Nanobiotechnology. 2023;21:334.
150. Xu H, Liu R, Zhou H, et al. Engineered small extracellular vesicles as bioactive materials: integrating engineering strategies for cargo loading and targeted delivery systems. Bioact Mater. 2026;59:96-134.
151. Khristov V, Weber SR, Caton-Darby M, Campbell G, Sundstrom JM. Diagnostic and therapeutic utility of extracellular vesicles in ocular disease. Int J Mol Sci. 2025;26:836.
152. Salunkhe S, Dheeraj, Basak M, Chitkara D, Mittal A. Surface functionalization of exosomes for target-specific delivery and in vivo imaging & tracking: strategies and significance. J Control Release. 2020;326:599-614.
153. Flores C, Mastantuono F, Huang L, et al. Extracellular vesicles in ophthalmology: from natural nanocarriers to engineered therapeutics. Bioengineering. 2026;13:275.
154. Tian Y, Zhang Y, Zhao J, et al. Combining MSC exosomes and cerium oxide nanocrystals for enhanced dry eye syndrome therapy. Pharmaceutics. 2023;15:2301.
155. Ma F, Feng J, Liu X, et al. A synergistic therapeutic nano-eyedrop for dry eye disease based on ascorbic acid-coupled exosomes. Nanoscale. 2023;15:1890-9.
156. Kang M, Hisey C, Tsai B, Nursalim Y, Blenkiron C, Chamley LW. Placental extracellular vesicles can be loaded with plasmid DNA. Mol Pharm. 2023;20:1898-913.
157. Wu P, Zhang B, Ocansey DKW, Xu W, Qian H. Extracellular vesicles: a bright star of nanomedicine. Biomaterials. 2021;269:120467.
158. Xie M, Wu Y, Zhang Y, et al. Membrane fusion-mediated loading of therapeutic siRNA into exosome for tissue-specific application. Adv Mater. 2024;36:e2403935.
159. Tang Q, Lu B, He J, et al. Exosomes-loaded thermosensitive hydrogels for corneal epithelium and stroma regeneration. Biomaterials. 2022;280:121320.
160. Sun X, Song W, Teng L, et al. MiRNA 24-3p-rich exosomes functionalized DEGMA-modified hyaluronic acid hydrogels for corneal epithelial healing. Bioact Mater. 2023;25:640-56.
161. Giri BR, Jakka D, Sandoval MA, Kulkarni VR, Bao Q. Advancements in ocular therapy: a review of emerging drug delivery approaches and pharmaceutical technologies. Pharmaceutics. 2024;16:1325.
162. Bairagi RD, Reon RR, Hasan MM, et al. Ocular drug delivery systems based on nanotechnology: a comprehensive review for the treatment of eye diseases. Discov Nano. 2025;20:75.
163. Lee J, Jeong J, Nguyen VP, Hong S, Paulus YM, Lee CH. Microneedles for controlled and sustained intraocular drug delivery. NPG Asia Mater. 2025;17:33.
164. Gratieri T, Gelfuso GM, Rocha EM, Sarmento VH, de Freitas O, Lopez RF. A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery. Eur J Pharm Biopharm. 2010;75:186-93.
165. Xie Y, Chai M, Xing Y, Zhou P, Wei P, Hua H. miRNA let-7f-5p-encapsulated labial gland MSC-derived EVs ameliorate experimental Sjögren’s syndrome by suppressing Th17 cells via targeting RORC/IL-17A signaling axis. J Nanobiotechnology. 2025;23:228.
167. Prina E, Mistry P, Sidney LE, et al. 3D microfabricated scaffolds and microfluidic devices for ocular surface replacement: a review. Stem Cell Rev Rep. 2017;13:430-41.
168. Bennet D, Estlack Z, Reid T, Kim J. A microengineered human corneal epithelium-on-a-chip for eye drops mass transport evaluation. Lab Chip. 2018;18:1539-51.
169. Kim M, Choi K, Lin A, Kim J. Current and future cornea chip models for advancing ophthalmic research and therapeutics. Adv Biol. 2025;9:e2400571.
170. Wan X, Gu J, Zhou X, et al. Establishment of human corneal epithelial organoids for ex vivo modelling dry eye disease. Cell Prolif. 2024;57:e13704.
171. Jeong SY, Choi WH, Jeon SG, et al. Establishment of functional epithelial organoids from human lacrimal glands. Stem Cell Res Ther. 2021;12:247.
172. Hayashi R, Okubo T, Kudo Y, et al. Generation of 3D lacrimal gland organoids from human pluripotent stem cells. Nature. 2022;605:126-31.
173. Bannier-Hélaouët M, Post Y, Korving J, et al. Exploring the human lacrimal gland using organoids and single-cell sequencing. Cell Stem Cell. 2021;28:1221-32.e7.
174. Yu C, Wan X, Wei J, et al. Human meibomian gland organoids to study epithelial homeostasis and dysfunction. Protein Cell. 2025;Epub ahead of print.
175. Seo J, Byun WY, Alisafaei F, et al. Multiscale reverse engineering of the human ocular surface. Nat Med. 2019;25:1310-8.
176. Wang Y, Yang F, Yang M, et al. Construction of dome-shaped 3D corneal epithelial tissue models based on eyeball-shaped gel microspheres. ACS Appl Mater Interfaces. 2024;16:31597-609.
177. Ferreira JN, Bhummaphan N, Chaisuparat R, et al. Unveiling senescence-associated ocular pathogenesis via lacrimal gland organoid magnetic bioassembly platform and HMGB1-Box A gene therapy. Sci Rep. 2024;14:21784.
178. Ma SC, Xie YL, Wang Q, Fu SG, Wu HZ. Application of eye organoids in the study of eye diseases. Exp Eye Res. 2024;247:110068.
179. Abdal Dayem A, Bin Jang S, Lim N, et al. Advances in lacrimal gland organoid development: techniques and therapeutic applications. Biomed Pharmacother. 2025;183:117870.
180. Dunn CM, Kameishi S, Grainger DW, Okano T. Strategies to address mesenchymal stem/stromal cell heterogeneity in immunomodulatory profiles to improve cell-based therapies. Acta Biomater. 2021;133:114-25.
181. Jammes M, Tabasi A, Bach T, Ritter T. Healing the cornea: exploring the therapeutic solutions offered by MSCs and MSC-derived EVs. Prog Retin Eye Res. 2025;105:101325.
182. Blanco NG, Machado NM, Castro LL, et al. Extracellular vesicles from different sources of mesenchymal stromal cells have distinct effects on lung and distal organs in experimental sepsis. Int J Mol Sci. 2023;24:8234.
183. Gupta S, Krishnakumar V, Soni N, Rao EP, Banerjee A, Mohanty S. Comparative proteomic profiling of small extracellular vesicles derived from iPSCs and tissue specific mesenchymal stem cells. Exp Cell Res. 2022;420:113354.
184. Li Y, Chen YH, Liu BY, et al. Deciphering the heterogeneity landscape of mesenchymal stem/stromal cell-derived extracellular vesicles for precise selection in translational medicine. Adv Healthc Mater. 2023;12:e2202453.
185. Dalle Carbonare L, Minoia A, Braggio M, et al. Extracellular vesicles in osteogenesis: comparative analysis of stem cell sources, conditioning strategies, and in vitro models toward advanced bone regeneration. Cells. 2025;15:27.
186. Gorgun C, Palamà MEF, Reverberi D, et al. Role of extracellular vesicles from adipose tissue- and bone marrow-mesenchymal stromal cells in endothelial proliferation and chondrogenesis. Stem Cells Transl Med. 2021;10:1680-95.
188. Lelek J, Zuba-Surma EK. Perspectives for future use of extracellular vesicles from umbilical cord- and adipose tissue-derived mesenchymal stem/stromal cells in regenerative therapies-synthetic review. Int J Mol Sci. 2020;21:799.
189. Tseng AM, Kandoi S, Heur M, Lee SY. Cell free regenerative extracellular vesicle therapy for ocular diseases. Curr Eye Res. 2025;50:1297-311.
190. Shimizu Y, Inoue Y, Matsuura N, et al. Mesenchymal stromal cell-derived extracellular vesicles in regenerative medicine: standardisation, bioengineering and clinical translation. Regen Ther. 2026;31:101058.
191. Fernández-Pérez AG, Herrera-González A, López-Naranjo EJ, et al. Extracellular vesicles from different mesenchymal stem cell types exhibit distinctive surface protein profiling and molecular characteristics: a comparative analysis. Int J Mol Sci. 2025;26:3393.
192. He J, Ren W, Wang W, et al. Exosomal targeting and its potential clinical application. Drug Deliv Transl Res. 2022;12:2385-402.
193. Tian B, Bilsbury E, Doherty S, et al. Ocular drug delivery: advancements and innovations. Pharmaceutics. 2022;14:1931.
194. Yang Y, Lockwood A. Topical ocular drug delivery systems: innovations for an unmet need. Exp Eye Res. 2022;218:109006.
195. Grassiri B, Zambito Y, Bernkop-Schnürch A. Strategies to prolong the residence time of drug delivery systems on ocular surface. Adv Colloid Interface Sci. 2021;288:102342.
196. Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: an overview. World J Pharmacol. 2013;2:47-64.
197. Xu Y, Wei C, Ma L, et al. 3D mesenchymal stem cell exosome-functionalized hydrogels for corneal wound healing. J Control Release. 2025;380:630-46.
198. Millán Cotto HA, Pathrikar TV, Hakim B, et al. Cationic-motif-modified exosomes for mRNA delivery to retinal photoreceptors. J Mater Chem B. 2024;12:7384-400.
199. Feng K, Xie X, Yuan J, et al. Reversing the surface charge of MSC-derived small extracellular vesicles by εPL-PEG-DSPE for enhanced osteoarthritis treatment. J Extracell Vesicles. 2021;10:e12160.
200. Wu H, Ye J, Zhang M, et al. A SU6668 pure nanoparticle-based eyedrops: toward its high drug Accumulation and Long-time treatment for corneal neovascularization. J Nanobiotechnology. 2024;22:290.
201. Foo JB, Looi QH, How CW, et al. Mesenchymal stem cell-derived exosomes and microRNAs in cartilage regeneration: biogenesis, efficacy, miRNA enrichment and delivery. Pharmaceuticals. 2021;14:1093.
202. Wang X, Thomsen P. Mesenchymal stem cell-derived small extracellular vesicles and bone regeneration. Basic Clin Pharmacol Toxicol. 2021;128:18-36.
203. Burnouf T, Agrahari V, Agrahari V. Extracellular vesicles as nanomedicine: hopes and hurdles in clinical translation. Int J Nanomedicine. 2019;14:8847-59.
204. Hua S, Bartold PM, Gulati K, Moran CS, Ivanovski S, Han P. Periodontal and dental pulp cell-derived small extracellular vesicles: a review of the current status. Nanomaterials. 2021;11:1858.
205. Tamrin SH, Phelps J, Nezhad AS, Sen A. Critical considerations in determining the surface charge of small extracellular vesicles. J Extracell Vesicles. 2023;12:e12353.
206. Saftics A, Abuelreich S, Romano E, et al. Single extracellular VEsicle nanoscopy. J Extracell Vesicles. 2023;12:e12346.
207. Sanghani A, Andriesei P, Kafetzis KN, Tagalakis AD, Yu-Wai-Man C. Advances in exosome therapies in ophthalmology-From bench to clinical trial. Acta Ophthalmol. 2022;100:243-52.
208. Wiklander OPB, Brennan MÁ, Lötvall J, Breakefield XO, El Andaloussi S. Advances in therapeutic applications of extracellular vesicles. Sci Transl Med. 2019;11:eaav8521.
209. Pariset E, Agache V, Millet A. Extracellular vesicles: isolation methods. Adv Biosyst. 2017;1:e1700040.
210. Yu LL, Zhu J, Liu JX, et al. A comparison of traditional and novel methods for the separation of exosomes from human samples. Biomed Res Int. 2018;2018:3634563.
211. Yuan F, Li YM, Wang Z. Preserving extracellular vesicles for biomedical applications: consideration of storage stability before and after isolation. Drug Deliv. 2021;28:1501-9.
212. Yi S, Kim J, Kim MJ, Yae CG, Kim KH, Kim HK. Development of human amniotic epithelial cell-derived extracellular vesicles as cell-free therapy for dry eye disease. Ocul Surf. 2024;34:370-80.
213. Syromiatnikova V, Prokopeva A, Gomzikova M. Methods of the large-scale production of extracellular vesicles. Int J Mol Sci. 2022;23:10522.
214. Trenkenschuh E, Richter M, Heinrich E, Koch M, Fuhrmann G, Friess W. Enhancing the stabilization potential of lyophilization for extracellular vesicles. Adv Healthc Mater. 2022;11:e2100538.
215. Evtushenko EG, Bagrov DV, Lazarev VN, Livshits MA, Khomyakova E. Adsorption of extracellular vesicles onto the tube walls during storage in solution. PLoS One. 2020;15:e0243738.
216. Melling GE, Carollo E, Conlon R, Simpson JC, Carter DRF. The challenges and possibilities of extracellular vesicles as therapeutic vehicles. Eur J Pharm Biopharm. 2019;144:50-6.
